ES-SCLC
Royalty Pharma Buys $885M Imdelltra Royalty Stake from BeOne
BeOne Medicines; Imdelltra; Amgen; Royalty Pharma; $885 million upfront; lung cancer; royalty deal; DLL3 bispecific; small cell lung cancer; ES-SCLC
Jazz Pharmaceuticals Advances Combination Therapy for Extensive-Stage Small Cell Lung Cancer
Jazz Pharmaceuticals, Zepzelca, lurbinectedin, atezolizumab, ES-SCLC, first-line maintenance therapy, small cell lung cancer, Phase 3 IMforte trial